Please assess the completion status of the following clinical trial:

Trial Title: Intra-dermal With Topical Imiquimod Pretreatment Versus Intra-muscular Hepatitis B Vaccination in IBD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged over 18 years old~* Confirmed IBD diagnosis (Ulcerative colitis, Crohns disease or IBD-Unclassified)~* HBsAg -ve / anti-HBs / antiHBc -ve~* Subjects must give written informed consent~* Subjects must be available to complete the study and comply with study procedures~Exclusion Criteria:~* Inability or unwilling to follow all required study procedures~* History of allergy or severe adverse reaction to the study vaccines, their components, topical imiquimod or aqueous cream~* Pregnant or lactating women~* HBsAg / anti-HBs / anti-HBc +ve~* Confirmed hepatitis C virus (HCV) (anti-HCV +ve) infection~* Fever (axillary temperature ≥ 38°C or oral temperature ≥ 38.5°C within 3 days of intended study vaccination, subjects can be recruited after the febrile episode subsides~* Have an active neoplastic disease~* Have any condition which the investigator believes may prevent successful completion of the study or interfere with results of the study~* Received an experimental agent (vaccine, drug, biologic, medication) within 1 month prior to vaccination or expect to receive an experimental agent during the study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intradermal hepatitis B vaccine with imiquimod (Type: EXPERIMENTAL): Subjects in the study arm will receive 20 mcg intradermal Engerix-B at two separate sites (10 mcg/0.5 ml) with topical imiquimod ointment pre-treatment 5 minutes before injection.
- Intramuscular hepatitis B vaccine with aqueous cream (Type: ACTIVE_COMPARATOR): Subjects in the control arm will receive 20 mcg intramuscular Engerix-B at two separate sites (10 mcg/ 0.5 ml) with topical placebo aqueous cream pretreatment 5 minutes before injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).